Program
evolocumab
Also written as “Evolocumab”, “Evolocumab AI/pen” and “Evolocumab Drug Substance A (Test)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 422 open or running | phase 4since Jan 3, 2018 | May 27, 2010 | May 29, 2027phase 4 · NCT05284747 |
| ECRI bv | 10 open or running | phase 4since Feb 12, 2019 | Feb 12, 2019 | none ahead |
| Hamad Medical | 10 open or running | phase 4since Oct 10, 2022 | Oct 10, 2022 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Nov 7, 2017 | Nov 7, 2017 | none ahead |
Also a collaborator on its studies: GE Healthcare and heartflow-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since May 27, 2010.
- Jun 13, 2016Phase 3 study in DyslipidemiasAmgen · NCT02833844 · 467 enrolled · United States, Australia, Belgium and more
- Jul 20, 2016Phase 3 study in DyslipidemiasAmgen · NCT02867813 · 5,035 enrolled · United States, Czechia, Hungary and more
- Mar 10, 2017Phase 3 study in DyslipidemiasAmgen · NCT03080935 · 1,600 enrolled · Belgium, Denmark, France and more
- Nov 7, 2017Hoffmann-La Roche's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Hoffmann-La RocheHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
- Jan 3, 2018Phase 4 study in HypercholesterolemiaAmgen · NCT03403374 · 30 enrolled · India
- Jan 18, 2018Phase 3 study in HypercholesterolemiaAmgen · NCT03433755 · 259 enrolled · China
- Jun 18, 2018Phase 3 study in Coronary Artery DiseaseAmgen · NCT03570697 · 164 enrolled · United States, Australia, Czechia and more
- Feb 12, 2019ECRI bv's first study: phase 4 study in Coronary Artery DiseaseNew to ECRI bvECRI bv · NCT03851263
- Mar 11, 2019Phase 3 study in Coronary DiseaseAmgen · NCT03872401 · 12,301 enrolled · United States, Argentina, Australia and more
- Mar 9, 2022Phase 4 study in Cardiovascular DiseasesAmgen · NCT05284747 · 6,019 enrolled · United States, Brazil, Sweden
- Oct 10, 2022Hamad Medical's first study: phase 4 study in ST Elevation Myocardial InfarctionNew to Hamad MedicalHamad Medical · NCT05579418 · 350 enrolled
- Feb 12, 2026Phase 1 study in Healthy ParticipantsAmgen · NCT07422285 · 405 enrolled · United States
- Apr 16, 2026Phase 1 study in Healthy ParticipantsAmgen · NCT07545226 · 405 enrolled · United States
- Aug 31, 2026Phase 4 study in Coronary Artery DiseaseAmgen · NCT07803679 · 308 planned
Ahead
- May 29, 2027Primary completion: phase 4 study in Cardiovascular DiseasesAmgen · NCT05284747
- Apr 30, 2029Primary completion: phase 4 study in Coronary Artery DiseaseAmgen · NCT07803679
TargetBeta
“A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07803679Coronary Artery Disease | 4 | Not yet recruiting | Amgen | Apr 30, 2029 | 308 |
| NCT07545226Healthy Participants · United States | 1 | Completed | Amgen | Sep 2, 2026 | 405 |
| NCT07422285Healthy Participants · United States | 1 | Completed | Amgen | Jul 24, 2026 | 405 |
| NCT05579418ST Elevation Myocardial Infarction | 4 | UNKNOWN | Hamad Medical | Oct 30, 2024 | 350 |
| NCT05284747Cardiovascular Diseases · United States, Brazil, Sweden | 4 | Active, not recruiting | Amgen | May 29, 2027 | 6,019 |
| NCT03872401Coronary Disease · United States, Argentina, Australia and more | 3 | Completed | Amgen | Jul 25, 2025 | 12,301 |
| NCT03851263Coronary Artery Disease | 4 | Withdrawn | ECRI bv | Aug 27, 2021 | 0 |
| NCT03570697Coronary Artery Disease · United States, Australia, Czechia and more | 3 | Completed | Amgen | Dec 18, 2020 | 164 |
| NCT03433755Hypercholesterolemia · China | 3 | Terminated | Amgen | Apr 24, 2020 | 259 |
| NCT03403374Hypercholesterolemia · India | 4 | Completed | Amgen | Nov 27, 2019 | 30 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03080935Dyslipidemias · Belgium, Denmark, France and more | 3 | Terminated | Amgen | Mar 4, 2022 | 1,600 |
| NCT02867813Dyslipidemias · United States, Czechia, Hungary and more | 3 | Completed | Amgen | Mar 21, 2022 | 5,035 |
| NCT02833844Dyslipidemias · United States, Australia, Belgium and more | 3 | Completed | Amgen | Jul 9, 2019 | 467 |
| NCT02739984Hypercholesterolemia · United States, Belgium, Canada and more | 3 | Completed | Amgen | Aug 3, 2017 | 424 |
| NCT02729025Dyslipidemias · United States, Canada, Netherlands | 3 | Completed | Amgen | Apr 5, 2018 | 129 |
| NCT02662569Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Completed | Amgen | Dec 6, 2017 | 986 |
| NCT02624869Hyperlipoproteinemia Type II · United States, Australia, Austria and more | 3 | Completed | Amgen | Jun 1, 2021 | 163 |
| NCT02585895Hypercholesterolemia · United States, Australia, Czechia and more | 3 | Completed | Amgen | Sep 1, 2016 | 39 |
| NCT02392559Hypercholesterolemia · United States, Australia, Austria and more | 3 | Completed | Amgen | Nov 25, 2019 | 158 |
| NCT02304484Hypercholesterolemia · United States, Argentina, Australia and more | 3 | Completed | Amgen | Mar 9, 2018 | 770 |
| NCT02207634Dyslipidemias · United States, Australia, Belgium and more | 3 | Completed | Amgen | Nov 11, 2016 | 1,974 |
| NCT02275156Hyperlipidemias · United States | 1 | Completed | Amgen | Dec 19, 2014 | 18 |
| NCT02189837Hypercholesterolemia · Australia | 3 | Completed | Amgen | Feb 13, 2015 | 89 |
| NCT01984424Hyperlipidemias · United States, Australia, Canada and more | 3 | Completed | Amgen | Nov 10, 2015 | 511 |
| NCT01953328Hyperlipidemias · Japan | 3 | Completed | Amgen | Jun 2014 | 409 |
| NCT01879319Hypercholesterolemia · United States, Canada | 3 | Completed | Amgen | Nov 15, 2013 | 164 |
| NCT01854918Hyperlipidemias · United States, Australia, Austria and more | 3 | Completed | Amgen | May 31, 2018 | 3,681 |
| NCT01849497Hypercholesterolemia · United States, Canada | 3 | Completed | Amgen | Sep 2, 2013 | 149 |
| NCT01813422Hypercholesterolemia · United States, Argentina, Australia and more | 3 | Completed | Amgen | Jul 12, 2016 | 970 |
| NCT01764633Dyslipidemias · United States, Argentina, Australia and more | 3 | Completed | Amgen | Nov 11, 2016 | 27,564 |
| NCT01763918Hyperlipidemias · United States, Australia, Canada and more | 3 | Completed | Amgen | Nov 27, 2013 | 331 |
| NCT01763905Hyperlipidemias · United States, Australia, Belgium and more | 3 | Completed | Amgen | Nov 19, 2013 | 307 |
| NCT01763866Hyperlipidemias · United States, Australia, Belgium and more | 3 | Completed | Amgen | Nov 12, 2013 | 2,067 |
| NCT01763827Hyperlipidemias · United States, Australia, Belgium and more | 3 | Completed | Amgen | Oct 10, 2013 | 615 |
| NCT01652703Hypercholesterolemia · Japan | 2 | Completed | Amgen | May 14, 2013 | 310 |
| NCT01624142Hyperlipoproteinemia Type II · United States, Australia, Belgium and more | 3 | Completed | Amgen | May 11, 2018 | 300 |
| NCT01588496Homozygous Familial Hypercholesterolemia · United States, Belgium, Canada and more | 3 | Completed | Amgen | Jan 31, 2014 | 58 |
| NCT01516879Hypercholesterolemia · United States, Australia, Austria and more | 3 | Completed | Amgen | Oct 14, 2013 | 905 |
| NCT01439880Hypercholesterolemia · United States, Australia, Belgium and more | 2 | Completed | Amgen | Jun 20, 2018 | 1,324 |
| NCT01380730Hyperlipidemias · United States, Canada, Czechia and more | 2 | Completed | Amgen | Apr 5, 2012 | 631 |
| NCT01375777Hyperlipidemias · United States, Australia, Belgium and more | 2 | Completed | Amgen | Mar 2, 2012 | 411 |
| NCT01375764Hyperlipidemias · United States, Australia, Belgium and more | 2 | Completed | Amgen | May 8, 2012 | 160 |
| NCT01375751Hyperlipoproteinemia Type II | 2 | Completed | Amgen | May 16, 2012 | 168 |
| NCT01133522Hyperlipidemias | 1 | Completed | Amgen | Sep 14, 2011 | 60 |
How it is read
Names in the registry
- “Evolocumab”, 39 entries
- “evolocumab”, 2 entries
- “Evolocumab AI/pen”, 2 entries
- “Evolocumab Drug Substance A (Test)”, 1 entry
- “Evolocumab Drug Substance B (Reference)”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 15 studies
- Hyperlipidemias, 12 studies
- Dyslipidemias, 4 studies
- Coronary Artery Disease, 3 studies
- Homozygous Familial Hypercholesterolemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.